Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
Oragenics, Inc. logo

AMEX · OGEN

Oragenics, Inc.

Healthcare · Biotechnology

$0.49

Down-$0.00 (-0.23%)

Updated Oct 7, 2026, 1:02 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.88M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.46 – $1.11
Volume
42.47K
Avg. volume
130.21K

Price performance · OGEN

OGEN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

OGEN closed at $0.49 after 20 trading sessions, down 6.93% for the selected period.

Last close
$0.49
Period change
-6.93%
Period low
$0.47
Period high
$0.52
Daily close
View OHLC price history
OGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$0.478$0.5049$0.478$0.486142.47K
Oct 2, 2026$0.48$0.50$0.48$0.487615.43K
Oct 1, 2026$0.4892$0.5189$0.48$0.4832.44K
Sep 30, 2026$0.4797$0.50$0.468$0.491814.37K
Sep 29, 2026$0.49$0.4901$0.4605$0.4842.64K
Sep 28, 2026$0.509$0.509$0.4605$0.471633.31K
Sep 25, 2026$0.52$0.52$0.4826$0.487813.35K
Sep 24, 2026$0.49$0.503$0.49$0.50317.42K
Sep 23, 2026$0.52$0.53$0.4851$0.48641.07K
Sep 22, 2026$0.5198$0.525$0.4965$0.5225.26K
Sep 21, 2026$0.4825$0.5199$0.4753$0.51937.85K
Sep 18, 2026$0.4962$0.52$0.4767$0.476743.02K
Sep 17, 2026$0.495$0.5229$0.4902$0.51948.95K
Sep 16, 2026$0.50$0.5163$0.48$0.5054.73K
Sep 15, 2026$0.487$0.4988$0.4756$0.487625.53K
Sep 14, 2026$0.484$0.499$0.4775$0.49924.66K
Sep 11, 2026$0.503$0.5036$0.478$0.47867.02K
Sep 10, 2026$0.5051$0.5053$0.5025$0.50339.24K
Sep 9, 2026$0.52$0.52$0.5052$0.5155.35K
Sep 8, 2026$0.51$0.5223$0.51$0.522312.63K

Latest OGEN news

The latest Smart Investors Daily articles mentioning OGEN.

Stock researchCompany · Overview

OGEN research

Overview

Company profile and research snapshot.

Company profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
OGEN recent ratings
DateFirmRatingTarget
Jun 3, 2021Goldman SachsNeutral—
Apr 16, 2020H.C. WainwrightNeutral—
Nov 15, 2019UBSNeutral—
Apr 26, 2019H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical develo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By